Baseline characteristics stratified by renal outcome in patients in the intensive and nonintensive pathway of the Myeloma XI trial
| . | Intensive pathway . | Nonintensive pathway . | ||||||
|---|---|---|---|---|---|---|---|---|
| Characteristic . | Decline in eGFR (≥25%) . | No change in eGFR (<25%) . | Improvement in eGFR (≥25%) . | P . | Decline in eGFR (≥25%) . | No change in eGFR (<25%) . | Improvement in eGFR (≥25%) . | P . |
| N (%) | 204 (14) | 905 (62) | 341 (23.5) | 178 (20) | 545 (62) | 161 (18) | ||
| Age, y | 66 (70-59) | 65 (70-58) | 66 (70-60) | .184 | 78 (75-82) | 78 (75-82) | 78 (75-82) | .706 |
| Median (IQR) | ||||||||
| Baseline GFR, median (IQR), mL per min per 1.73 m2 | 80 (68-90) | 75 (62-89) | 51 (38-59.5) | <.001 | 72 (58-87) | 62 (48-77) | 45 (33-57) | <.001 |
| 12-mo GFR, median (IQR), mL per min per 1.73 m2 | 51 (43-57) | 73 (60-89) | 76 (60-90) | <.001 | 44 (35-52) | 60 (47-76) | 67 (51-83) | <.001 |
| Baseline dFLC, n (%), mg | <.001 | .07 | ||||||
| <500 | 142 (70) | 575 (64) | 163 (48) | 114 (64) | 332 (61) | 86 (53) | ||
| 500-1000 | 25 (12) | 143 (16) | 51 (15) | 27 (15) | 86 (16) | 20 (12) | ||
| >1000 | 36 (18) | 181 (20) | 124 (37) | 36 (20) | 124 (23) | 55 (34) | ||
| Missing | 1 (0.5) | 6 (0.7) | 3 (0.9) | 1 (0.6) | 3 (0.6) | |||
| Baseline dFLC κ, median (IQR), mg/L (in κ patients) | 241 (26-637) | 264 (37-817) | 426 (83-1531) | <.001 | 240 (33-781) | 374 (80-1027) | 477 (103-1483) | .017 |
| Baseline dFLC λ, median (IQR), mg/L (in λ patients) | 289 (49-694) | 294 (47-801) | 689 (174-2629) | <.001 | 213 (25-782) | 279 (47-755) | 450 (131-2131) | .07 |
| dFLC response, n (%) | .001 | .002 | ||||||
| <50% | 9 (4.4) | 15 (1.6) | 6 (1.8) | 28 (15.6) | 48 (8.7) | 11 (6.8) | ||
| 50%-90% | 9 (4.4) | 58 (6.4) | 17 (5) | 28 (15.7) | 128 (23.5) | 41 (25.5) | ||
| >90% | 109 (53.4) | 516 (57) | 236 (69.2) | 57 (32) | 216 (39.6) | 72 (44.7) | ||
| Baseline dFLC <100 | 75 (37) | 310 (34) | 79 (23) | 63 (35) | 152 (27.8) | 36 (22.3) | ||
| Missing | 2 (1) | 6 (0.66) | 3 (0.9) | 2 (1) | 1 (0.1) | 1 (0.6) | ||
| . | Intensive pathway . | Nonintensive pathway . | ||||||
|---|---|---|---|---|---|---|---|---|
| Characteristic . | Decline in eGFR (≥25%) . | No change in eGFR (<25%) . | Improvement in eGFR (≥25%) . | P . | Decline in eGFR (≥25%) . | No change in eGFR (<25%) . | Improvement in eGFR (≥25%) . | P . |
| N (%) | 204 (14) | 905 (62) | 341 (23.5) | 178 (20) | 545 (62) | 161 (18) | ||
| Age, y | 66 (70-59) | 65 (70-58) | 66 (70-60) | .184 | 78 (75-82) | 78 (75-82) | 78 (75-82) | .706 |
| Median (IQR) | ||||||||
| Baseline GFR, median (IQR), mL per min per 1.73 m2 | 80 (68-90) | 75 (62-89) | 51 (38-59.5) | <.001 | 72 (58-87) | 62 (48-77) | 45 (33-57) | <.001 |
| 12-mo GFR, median (IQR), mL per min per 1.73 m2 | 51 (43-57) | 73 (60-89) | 76 (60-90) | <.001 | 44 (35-52) | 60 (47-76) | 67 (51-83) | <.001 |
| Baseline dFLC, n (%), mg | <.001 | .07 | ||||||
| <500 | 142 (70) | 575 (64) | 163 (48) | 114 (64) | 332 (61) | 86 (53) | ||
| 500-1000 | 25 (12) | 143 (16) | 51 (15) | 27 (15) | 86 (16) | 20 (12) | ||
| >1000 | 36 (18) | 181 (20) | 124 (37) | 36 (20) | 124 (23) | 55 (34) | ||
| Missing | 1 (0.5) | 6 (0.7) | 3 (0.9) | 1 (0.6) | 3 (0.6) | |||
| Baseline dFLC κ, median (IQR), mg/L (in κ patients) | 241 (26-637) | 264 (37-817) | 426 (83-1531) | <.001 | 240 (33-781) | 374 (80-1027) | 477 (103-1483) | .017 |
| Baseline dFLC λ, median (IQR), mg/L (in λ patients) | 289 (49-694) | 294 (47-801) | 689 (174-2629) | <.001 | 213 (25-782) | 279 (47-755) | 450 (131-2131) | .07 |
| dFLC response, n (%) | .001 | .002 | ||||||
| <50% | 9 (4.4) | 15 (1.6) | 6 (1.8) | 28 (15.6) | 48 (8.7) | 11 (6.8) | ||
| 50%-90% | 9 (4.4) | 58 (6.4) | 17 (5) | 28 (15.7) | 128 (23.5) | 41 (25.5) | ||
| >90% | 109 (53.4) | 516 (57) | 236 (69.2) | 57 (32) | 216 (39.6) | 72 (44.7) | ||
| Baseline dFLC <100 | 75 (37) | 310 (34) | 79 (23) | 63 (35) | 152 (27.8) | 36 (22.3) | ||
| Missing | 2 (1) | 6 (0.66) | 3 (0.9) | 2 (1) | 1 (0.1) | 1 (0.6) | ||
Boldface P values signify statistical significance (P < .05).